A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)

Trial Profile

A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Tirasemtiv (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions
  • Acronyms VIGOR-ALS
  • Sponsors Cytokinetics
  • Most Recent Events

    • 06 Dec 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Nov 2017 According to a Cytokinetics media release, the company will seek advice from the academic leadership of VITALITY-ALS and its clinical investigators, regulatory authorities and other consultants before making decisions about continuing treatment with tirasemtiv in VIGOR-ALS.
    • 02 Aug 2017 According to a Cytokinetics media release, the company expects to continue to enroll patients who complete VITALITY-ALS study into VIGOR-ALS throughout 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top